Webinar | November 18, 2026

From Clinical Success To Commercial Readiness

For orphan drugs and precision medicines, API is scarce or costly, and that leaves little room for development detours. Early decisions can make or break a program's long-term success, and Phase 2 is where clinical momentum meets commercial reality. Dosage form, container, and delivery system (vial, prefilled syringe, or autoinjector) all have to satisfy technical, regulatory, and supply chain demands at once. Changes made late are expensive.

Alessandro Chreim, Global SME, Sterile Drug Products, Pharma Services at Thermo Fisher Scientific, has more than 10 years of experience in technology transfer, product development, and sterile fill-and-finish manufacturing. His work has spanned the product lifecycle, from early-stage development to commercial manufacturing, and he holds a master of science degree in chemistry and pharmaceutical technology from the University of Milan.

He takes up a pointed question: what does commercial readiness really mean, and which decisions matter most as an early clinical formulation becomes a scalable product?

Access The Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online